[go: up one dir, main page]

MX358099B - Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. - Google Patents

Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.

Info

Publication number
MX358099B
MX358099B MX2013013360A MX2013013360A MX358099B MX 358099 B MX358099 B MX 358099B MX 2013013360 A MX2013013360 A MX 2013013360A MX 2013013360 A MX2013013360 A MX 2013013360A MX 358099 B MX358099 B MX 358099B
Authority
MX
Mexico
Prior art keywords
methods
immunodeficiency virus
human immunodeficiency
antibodies
neutralize
Prior art date
Application number
MX2013013360A
Other languages
English (en)
Other versions
MX2013013360A (es
Inventor
Scheid Johannes
Nussenzweig Michel
J Bjorkman Pamela
Diskin Ron
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX2013013360A publication Critical patent/MX2013013360A/es
Publication of MX358099B publication Critical patent/MX358099B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos ampliamente neutralizantes dirigidos a epítopos del Virus de Inmunodeficiencia Humana, o VIH. La invención también provee composiciones que contienen anticuerpos de VIH usadas para la profilaxis y métodos para el diagnóstico y el tratamiento de la infección por VIH.
MX2013013360A 2011-05-17 2012-05-17 Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos. MX358099B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486960P 2011-05-17 2011-05-17
PCT/US2012/038400 WO2012158948A1 (en) 2011-05-17 2012-05-17 Human immunodeficiency virus neutralizing antibodies adn methods of use thereof

Publications (2)

Publication Number Publication Date
MX2013013360A MX2013013360A (es) 2014-09-22
MX358099B true MX358099B (es) 2018-08-06

Family

ID=47177348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013360A MX358099B (es) 2011-05-17 2012-05-17 Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.

Country Status (19)

Country Link
US (5) US9783594B2 (es)
EP (2) EP3865507A1 (es)
JP (6) JP6323718B2 (es)
CN (4) CN103797029B (es)
AU (6) AU2012255266B2 (es)
CA (1) CA2836468C (es)
CY (1) CY1124043T1 (es)
DK (1) DK2710033T3 (es)
EA (2) EA032929B1 (es)
ES (1) ES2895523T3 (es)
HR (1) HRP20210375T1 (es)
HU (1) HUE053545T2 (es)
IL (4) IL295205B2 (es)
LT (1) LT2710033T (es)
MX (1) MX358099B (es)
PL (1) PL2710033T3 (es)
PT (1) PT2710033T (es)
SI (1) SI2710033T1 (es)
WO (1) WO2012158948A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783594B2 (en) * 2011-05-17 2017-10-10 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
US9890207B2 (en) 2011-07-25 2018-02-13 California Institute Of Technology Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
CA2858716C (en) 2011-12-08 2021-10-12 Peter D. Kwong Neutralizing antibodies to hiv-1 and their use
WO2013192589A1 (en) 2012-06-21 2013-12-27 California Institute Of Technology Antibodies targeting hiv escape mutants
US10308707B2 (en) * 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015117008A2 (en) * 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
CN108064248B (zh) * 2014-09-30 2022-03-15 生物控股有限公司 人源抗二肽重复(dpr)抗体
WO2016062988A1 (en) * 2014-10-22 2016-04-28 Crescendo Biologics Limited Vh scaffold
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
HRP20200583T1 (hr) 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protutijela koja neutraliziraju gp120 i njihova upotreba
BR112018008011A2 (en) 2015-10-25 2018-10-30 Sanofi trypecific and / or trivalent binding proteins for prevention or treatment of HIV infection
CA3003878A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 gp41 and their use
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
KR20240036142A (ko) 2016-04-13 2024-03-19 사노피 3특이성 및/또는 3가 결합 단백질
US10882922B2 (en) 2016-04-13 2021-01-05 Sanofi Trispecific and/or trivalent binding proteins
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
CA3039089A1 (en) * 2016-10-03 2018-04-12 Duke University Methods to identify immunogens by targeting improbable mutations
EP3525821A4 (en) 2016-10-17 2020-09-09 University of Maryland MULTI-SPECIFIC ANTIBODIES TARGETING THE HUMAN IMMUNODEFICIENCY VIRUS AND THEIR METHODS OF USE
JP7041898B2 (ja) 2016-12-27 2022-03-25 ザ ロックフェラー ユニバーシティー 広域中和抗ｈｉｖ－１抗体およびその使用方法
US10875890B2 (en) * 2017-03-14 2020-12-29 Oregon State University Peptide inhibitors targeting the Neisseria gonorrhoeae pivotal anaerobic respiration factor AniA
EP3600405B1 (en) 2017-03-24 2025-08-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
US20200172601A1 (en) 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
SG11202003212PA (en) 2017-10-10 2020-05-28 Sanofi Sa Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
WO2019165122A1 (en) 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2019173802A1 (en) * 2018-03-09 2019-09-12 Atreca, Inc. Anti-hiv antibodies
CN110305219B (zh) * 2018-03-27 2021-05-04 清华大学 一种包含嵌合抗原受体（car）修饰的t细胞在制备细胞药物中的用途
BR112020021855A2 (pt) 2018-04-27 2021-02-23 Biogen Ma Inc. anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
BR112020024048A2 (pt) * 2018-05-25 2021-02-17 Temple University-Of The Commonwealth System Of Higher Education composição, e, métodos para descolonizar um organismo microbiano, para destruir ou interromper ou inibir ou reduzir a formação de biofilme de um organismo microbiano e para tratar uma infecção microbiana em um indivíduo.
BR112020023181A2 (pt) 2018-06-11 2021-02-09 Dow Global Technologies Llc máquinas de fatiamento e métodos para formar rolos de filmes revestidos com as mesmas
MX2020012615A (es) 2018-06-11 2021-01-29 Dow Global Technologies Llc Procesos para la fabricacion de peliculas recubiertas y precursores de poliuretano sin solvente que pueden usarse para la fabricacion de peliculas recubiertas.
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
US12441782B2 (en) * 2018-09-14 2025-10-14 The Rockefeller University Anti-HIV antibody 10-1074 variants
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
BR112021006558A2 (pt) 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
EP3870222A4 (en) * 2018-10-22 2022-07-27 International AIDS Vaccine Initiative ANTI-HIV ANTIBODIES
SI3938047T1 (sl) 2019-03-22 2022-10-28 Gilead Sciences, Inc. Premoščene triciklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202231277A (zh) * 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP3831848A1 (en) * 2019-12-02 2021-06-09 Universität zu Köln Broadly neutralizing antibodies against hiv
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
TW202146463A (zh) * 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
TWI845826B (zh) 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
MX2023001507A (es) 2020-08-07 2023-03-06 Gilead Sciences Inc Profarmacos de analogos de nucleotidos de fosfonamida y su uso farmaceutico.
PH12023500005A1 (en) 2020-08-25 2023-08-14 Gilead Sciences Inc Multi-specific antigen binding molecules targeting hiv and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
CN115518151A (zh) * 2021-06-24 2022-12-27 前沿生物药业(南京)股份有限公司 一种人类免疫缺陷病毒中和抗体制剂及其用途
WO2023019019A2 (en) * 2021-08-13 2023-02-16 Abwiz Bio, Inc. Humanization, affinity maturation, and optimization methods for proteins and antibodies
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
FI4445900T3 (fi) 2021-12-03 2025-08-05 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
JP2025501273A (ja) 2021-12-31 2025-01-17 北京三▲諾▼佳邑生物技▲術▼有限▲責▼任公司 Ｈｉｖ感染細胞を標的とするキメラ抗原受容体ｔ細胞
WO2023158505A1 (en) * 2022-02-16 2023-08-24 Prothione Llc Compositions and methods for the treatment of human immunodeficiency virus
EP4499227A1 (en) 2022-03-26 2025-02-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Bispecific antibodies to hiv-1 env and their use
EP4499228A1 (en) 2022-03-28 2025-02-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 env and their use
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4547659A1 (en) 2022-07-01 2025-05-07 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EP4554628A1 (en) 2022-07-12 2025-05-21 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
CN117275589A (zh) * 2023-08-28 2023-12-22 大理大学 Hiv抗体亲和性预测方法、系统、设备及介质
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184416A1 (en) 2024-02-27 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single-domain antibodies and bispecific antibodies against hiv-1 and their use
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025260028A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
IL89567A0 (en) 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
US5445960A (en) * 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5830663A (en) 1991-08-10 1998-11-03 Medical Research Council In situ recombinant PCR within single cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0690132B1 (en) 1993-03-11 2003-12-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-hiv monoclonal antibody
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
DE69428896T2 (de) 1993-05-07 2002-06-20 Akzo Nobel N.V., Arnheim/Arnhem Hiv immunogene komplexe
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO2002002606A2 (en) * 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2002068649A2 (en) * 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
EP1425694A2 (en) 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
WO2003044036A1 (en) 2001-11-19 2003-05-30 Applied Molecular Evolution, Inc. Tumor specific monoclonal antibodies
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US20030232387A1 (en) 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
GB0313132D0 (en) 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
US7824681B2 (en) * 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
CN101506358B (zh) * 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
JP4895727B2 (ja) * 2006-08-28 2012-03-14 シスメックス株式会社 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法
CN101802008B (zh) 2007-08-21 2015-04-01 安美基公司 人类c-fms抗原结合蛋白
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2098536A1 (en) * 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
JP5522405B2 (ja) 2008-04-25 2014-06-18 協和発酵キリン株式会社 安定な多価抗体
JP2011526591A (ja) * 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
ES2511051T3 (es) 2009-05-29 2014-10-22 Morphosys Ag Colección de anticuerpos sintéticos para tratar enfermedades
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) * 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
US9783594B2 (en) * 2011-05-17 2017-10-10 The Rockefeller University Human immunodeficiency virus neutralizing antibodies and methods of use thereof
US9493549B2 (en) * 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
US9890207B2 (en) * 2011-07-25 2018-02-13 California Institute Of Technology Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
CA2858716C (en) 2011-12-08 2021-10-12 Peter D. Kwong Neutralizing antibodies to hiv-1 and their use
CN118955699A (zh) * 2012-10-18 2024-11-15 洛克菲勒大学 广泛中和性抗hiv抗体
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers

Also Published As

Publication number Publication date
EA201391713A1 (ru) 2014-07-30
IL313030A (en) 2024-07-01
AU2012255266A1 (en) 2013-12-19
JP7076721B2 (ja) 2022-05-30
CN103797029B (zh) 2016-08-17
CN112225798A (zh) 2021-01-15
AU2012255266B2 (en) 2017-05-25
US10889633B2 (en) 2021-01-12
JP2018161126A (ja) 2018-10-18
PL2710033T3 (pl) 2021-10-25
US11634478B2 (en) 2023-04-25
AU2019200972B2 (en) 2020-04-16
IL276182B (en) 2022-09-01
EP3865507A1 (en) 2021-08-18
JP2025061692A (ja) 2025-04-11
AU2019200972A1 (en) 2019-02-28
EA032929B1 (ru) 2019-08-30
IL229469B (en) 2020-08-31
JP2020202827A (ja) 2020-12-24
US12071470B2 (en) 2024-08-27
AU2022204340B2 (en) 2025-03-06
US20230365661A1 (en) 2023-11-16
US20140328862A1 (en) 2014-11-06
EP2710033A1 (en) 2014-03-26
BR112013029550A2 (pt) 2022-04-19
US12428472B2 (en) 2025-09-30
EP2710033B1 (en) 2021-01-20
US20210230254A1 (en) 2021-07-29
JP6720242B2 (ja) 2020-07-08
LT2710033T (lt) 2021-06-10
HUE053545T2 (hu) 2021-07-28
ES2895523T3 (es) 2022-02-21
US20180079800A1 (en) 2018-03-22
IL295205A (en) 2022-10-01
AU2020201993B2 (en) 2022-03-31
CY1124043T1 (el) 2022-05-27
AU2017204563B2 (en) 2018-11-22
IL295205B1 (en) 2024-07-01
WO2012158948A1 (en) 2012-11-22
SI2710033T1 (sl) 2021-05-31
JP7622953B2 (ja) 2025-01-28
CN106432484B (zh) 2020-10-30
IL276182A (en) 2020-09-30
AU2025204249A1 (en) 2025-06-26
CN112225798B (zh) 2023-07-18
DK2710033T3 (da) 2021-03-08
CN116948019A (zh) 2023-10-27
EP2710033A4 (en) 2015-04-22
AU2020201993A1 (en) 2020-04-09
HRP20210375T1 (hr) 2021-07-09
MX2013013360A (es) 2014-09-22
JP7368812B2 (ja) 2023-10-25
JP2014516527A (ja) 2014-07-17
US20240254206A1 (en) 2024-08-01
JP2024001150A (ja) 2024-01-09
JP2022115945A (ja) 2022-08-09
IL229469A0 (en) 2014-01-30
US9783594B2 (en) 2017-10-10
AU2022204340A1 (en) 2022-07-14
IL295205B2 (en) 2024-11-01
CN106432484A (zh) 2017-02-22
JP6323718B2 (ja) 2018-05-16
AU2017204563A1 (en) 2017-07-27
CN103797029A (zh) 2014-05-14
CA2836468A1 (en) 2012-11-22
EA201990685A1 (ru) 2019-12-30
CA2836468C (en) 2021-05-04
PT2710033T (pt) 2021-03-11

Similar Documents

Publication Publication Date Title
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
MX369307B (es) Compuestos terapeuticos utiles para tratamiento profilactico o terapeutico de infeccion por virus de inmunodeficiencia humana.
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
NI201700019A (es) Anticuerpos anti tigit
MX2017001279A (es) Usos y composiciones de la flagelina.
MX391043B (es) Formulaciones de anticuerpo y metodos.
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MX2014013678A (es) Agentes para neutralizacion de influenza.
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
UY35993A (es) Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina
IN2014MN01907A (es)
PE20160596A1 (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
MX364704B (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
WO2014040025A3 (en) Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
BR112017003252A2 (pt) terapia com anticorpos contra hiv como substituto de tratamento
UY34128A (es) Métodos, composiciones y kits para determinar el virus de la inmunodeficiencia humana (vih)?.
MX386783B (es) Compuestos peptidomiméticos que neutralizan el virus influenza.
ECSP17016755A (es) Anticuerpos anti tigit
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv
CU20140006A7 (es) Moléculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenético 1 y grupo filogenético 2 y virus de la influenza b

Legal Events

Date Code Title Description
FG Grant or registration